The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).
 
Tomohiro Matsushima
No Relationships to Disclose
 
Yukiya Narita
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
 
Toshihiro Misumi
No Relationships to Disclose
 
Yasuhiro Sakamoto
No Relationships to Disclose
 
Hiroshi Matsuoka
No Relationships to Disclose
 
Hiroaki Tanioka
No Relationships to Disclose
 
Takeshi Kawakami
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroto Miwa
No Relationships to Disclose
 
Hirokazu Shoji
Research Funding - Amgen (Inst); Astellas Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Atsushi Ishiguro
No Relationships to Disclose
 
Takanobu Yamada
Honoraria - Johnson & Johnson/Janssen; Ono Pharmaceutical; Taiho Pharmaceutical
 
Sachio Fushida
Speakers' Bureau - Bristol-Myers Squibb Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kou Miura
No Relationships to Disclose
 
Katsunori Shinozaki
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck; Mochida Pharmaceutical Co. Ltd.; Nihonkayaku; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda
 
Takuro Mizukami
Honoraria - Asahi Kasei; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Otsuka; Taiho Pharmaceutical; Takeda
Research Funding - Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshikazu Moriwaki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Eisai (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Seiichiro Mitani
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical